Skip to main content
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1952 Jul 1;96(1):99–106. doi: 10.1084/jem.96.1.99

TRANSITORY APPEARANCE OF TYPE 2 NEUTRALIZING ANTIBODY IN PATIENTS INFECTED WITH TYPE 1 POLIOMYELITIS VIRUS

Albert B Sabin 1
PMCID: PMC2136122  PMID: 14946332

Abstract

Neutralizing antibodies for Type 2 (Lansing) poliomyelitis virus were tested periodically in a group of 18 patients from whom Type 1 poliomyelitis virus was recovered. Data for homotypic neutralizing antibodies and Type 2 complement-fixing antibodies were also available on the majority of these patients. The results indicated that Type 2 neutralizing antibodies first appeared or significantly increased in titer in 11 of the 18 patients during the first 2 to 4 weeks after onset. In most patients the Type 2 neutralizing antibody either completely disappeared at 3 months (in one patient between 2 and 4 weeks) or dropped in titer, while the Type 1 or homotypic antibody persisted in high titer. These results are interpreted as indicating that the Type 1 and Type 2 poliomyelitis viruses share a common antigen, and that the heterotypic anti-body response is transitory while the homotypic neutralizing antibody persists for a longer time.

Full Text

The Full Text of this article is available as a PDF (445.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CASALS J., OLITSKY P. K., ANSLOW R. O. A specific complement-fixation test for infection with poliomyelitis virus. J Exp Med. 1951 Aug;94(2):123–137. doi: 10.1084/jem.94.2.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. CASALS J., OLITSKY P. K., SABIN A. B. Development, persistence, and significance of type 2, poliomyelitis complement-fixing antibody in man. J Exp Med. 1952 Jul;96(1):35–53. doi: 10.1084/jem.96.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. CLARK E. M., RHODES A. J. Poliomyelitis in Canadian Eskimos, laboratory studies. II. Can J Med Sci. 1951 Aug;29(4):216–235. doi: 10.1139/cjms51-027. [DOI] [PubMed] [Google Scholar]
  4. HAMMON W. M., ROBERTS E. C. Serum neutralizing antibodies to the infecting strain of virus in poliomyelitis patients. Proc Soc Exp Biol Med. 1948 Nov;69(2):256–258. doi: 10.3181/00379727-69-16682. [DOI] [PubMed] [Google Scholar]
  5. LAHELLE O. Complement-fixation test for the Lansing strain of poliomyelitis virus. Am J Hyg. 1951 Nov;54(3):391–401. doi: 10.1093/oxfordjournals.aje.a119494. [DOI] [PubMed] [Google Scholar]
  6. POLLARD M., HSIANG C. M., SHARP G. R. Preparation of specific complement-fixing antigens from the three prototypes of poliomyelitis viruses. Proc Soc Exp Biol Med. 1952 Jan;79(1):48–50. doi: 10.3181/00379727-79-19268. [DOI] [PubMed] [Google Scholar]
  7. STEIGMAN A. J., SABIN A. B. Antibody response of patients with poliomyelitis to virus recovered from their own alimentary tract. J Exp Med. 1949 Oct;90(4):349–372. doi: 10.1084/jem.90.4.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. SVEDMYR A., ENDERS J. F., HOLLOWAY A. Complement fixation with Brunhilde and Lansing poliomyelitis viruses propagated in tissue culture. Proc Soc Exp Biol Med. 1952 Feb;79(2):296–300. doi: 10.3181/00379727-79-19357. [DOI] [PubMed] [Google Scholar]
  9. TURNER T. B., HOLLANDER D. H., BUCKLEY S., KOKKO U. P., WINSOR C. P. Age incidence and seasonal development of neutralizing antibodies to lansing poliomyelitis virus. Am J Hyg. 1950 Nov;52(3):323–347. doi: 10.1093/oxfordjournals.aje.a119427. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES